BioSpace News Archive

Iovance Biotherapeutics, Inc. today announced that senior leadership plans to present at the following conferences: Chardan’s 7th Annual Genetic Medicine and Cell Therapy Manufacturing Summit Fireside Chat: April 24, 2023 at 1:00 p.m. ET.

Aclarion, Inc. announced today the publication of two-year durability data which demonstrates improved surgical outcomes for discogenic low back pain (DLBP) surgeries at chemically painful lumbar discs identified by Nociscan.

Tiziana Life Sciences Ltd. today announces that it has received a notification from the Nasdaq Stock Market LLC (“Nasdaq”) Listing Qualifications Department informing the Company that it has regained compliance with the Nasdaq listing minimum bid price requirement for continued listing on the Nasdaq Capital Market exchange.

Health Canada has issued a Notice of Compliance (NOC) approving BEYFORTUS™ (nirsevimab) for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease (LRTD) in newborns and infants during their first RSV season, and children up to 24 months of age who remain vulnerable to severe RSV disease through their second RSV season.

Visolis today announced a partnership with Ginkgo Bioworks which is building the leading platform for cell programming and biosecurity.

Viatris Inc. and Mapi Pharma today announced that recent data from ongoing studies of GA Depot 40 mg will be presented at the American Academy of Neurology (AAN) 75th Annual Meeting in Boston taking place April 22-27.

Nevro Corp. announced today that it is participating in the following investor conferences.

Bausch + Lomb Corporation today announced the U.S. launch of StableVisc™ cohesive ophthalmic viscosurgical device (OVD) as well as TotalVisc™ Viscoelastic System.

Detailed results from the NEURO-TTRansform Phase III trial in patients with hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN) showed AstraZeneca and Ionis’ eplontersen met all co-primary endpoints and secondary endpoints at 66 weeks versus an external placebo group.

iSpecimen Inc. today announced that Tracy Curley, CEO of iSpecimen, will participate in the Aegis Conference to be held virtually on May 2-4, 2023.